Statistical Issues in Translational Cancer Research

The explosion of knowledge about the basic biological processes and the genetics of cancer has led to increasing optimism that this knowledge can be put to practical clinical use in the near future. Indeed, important examples of translational approaches can already be found in the areas of drug discovery and development, disease diagnosis and classification, selection of therapeutic regimens for individual patients, and designing clinical trials. These are important developments but, as with any new approach, there is a danger of unwarranted enthusiasm and premature clinical application of laboratory results based on insufficient evidence. To carry out the translation of knowledge into practice with maximal efficiency and effectiveness, it is essential to conduct studies with appropriate designs and analyses based on sound statistical principles. This article provides an overview of some of these principles applied to assay development, validation of predictive models, and the design of clinical trials for targeted therapies.

[1]  Making Efficient Use of Patients in Designing Phase III Trials Investigating Simultaneously a Set of Targeted Therapies with Different Targets , 2006, Biometrical journal. Biometrische Zeitschrift.

[2]  Simon Lin,et al.  Methods of microarray data analysis III , 2002 .

[3]  Viswanath Devanarayan,et al.  Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement , 2006, Pharmaceutical Research.

[4]  Jeremy MG Taylor,et al.  Validation of Biomarker-Based Risk Prediction Models , 2008, Clinical Cancer Research.

[5]  C Hill,et al.  Interpretation of microarray data in cancer , 2007, British Journal of Cancer.

[6]  R. Simon,et al.  Evaluating the Efficiency of Targeted Designs for Randomized Clinical Trials , 2004, Clinical Cancer Research.

[7]  Stefan Michiels,et al.  Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis? , 2007, European journal of cancer.

[8]  R. Simon,et al.  On the efficiency of targeted clinical trials , 2005, Statistics in medicine.

[9]  Daniel J Sargent,et al.  Clinical trial designs for predictive marker validation in cancer treatment trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Biomarkers in Clinical Drug Development , 2003 .

[11]  William D. Figg,et al.  Validation of Analytic Methods for Biomarkers Used in Drug Development , 2008, Clinical Cancer Research.

[12]  R Spang,et al.  Molecular Diagnosis , 2005, Methods of Information in Medicine.

[13]  B. Korf,et al.  Molecular diagnosis (2) , 1995, The New England journal of medicine.

[14]  Stephen Senn,et al.  Statistical Issues in Drug Development , 1997 .

[15]  D. Ransohoff.  Rules of evidence for cancer molecular-marker discovery and validation , 2004, Nature Reviews Cancer.

[16]  F. Harrell,et al.  Regression modelling strategies for improved prognostic prediction. , 1984, Statistics in medicine.

[17]  W. Sauerbrei,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.

[18]  Harald Binder,et al.  Assessment of survival prediction models based on microarray data , 2007, Bioinform..

[19]  R. Simon,et al.  Sample size planning for developing classifiers using high-dimensional DNA microarray data. , 2007, Biostatistics.

[20]  R Simon,et al.  Diagnostic and prognostic prediction using gene expression profiles in high-dimensional microarray data , 2003, British Journal of Cancer.

[21]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[22]  D. G. Altman,et al.  Statistical aspects of prognostic factor studies in oncology. , 1994, British Journal of Cancer.

[23]  D. Sargent,et al.  Statistical issues in tumor marker studies. , 2000, Archives of pathology & laboratory medicine.

[24]  R. Simon,et al.  Adaptive Signature Design: An Adaptive Clinical Trial Design for Generating and Prospectively Testing A Gene Expression Signature for Sensitive Patients , 2005, Clinical Cancer Research.

[25]  Insuk Sohn,et al.  Statistical Challenges in Preprocessing in Microarray Experiments in Cancer , 2008, Clinical Cancer Research.

[26]  Kimberly F. Johnson.  Methods of Microarray Data Analysis II , 2002, Springer US.

[27]  D G Altman,et al.  What do we mean by validating a prognostic model? , 2000, Statistics in medicine.

[28]  M. Fernö,et al.  "Good Old" clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. , 2004, European journal of cancer.

[29]  R. Simon,et al.  Use of genomic signatures in therapeutics development in oncology and other diseases , 2006, The Pharmacogenomics Journal.

[30]  Sue-Jane Wang,et al.  Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset , 2007, Pharmaceutical statistics.

[31]  A. Venot,et al.  Methodological and statistical problems in the construction of composite measurement scales: a survey of six medical and epidemiological journals. , 1995, Statistics in medicine.

[32]  E. Wit.  Design and Analysis of DNA Microarray Investigations , 2004, Human Genomics.

[33]  George Y H Chi,et al.  A method for testing a prespecified subgroup in clinical trials , 2007, Statistics in medicine.

[34]  D. Ransohoff.  Bias as a threat to the validity of cancer molecular-marker research , 2005, Nature reviews. Cancer.

[35]  Steven A Carr,et al.  Protein biomarker discovery and validation: the long and uncertain path to clinical utility , 2006, Nature Biotechnology.